Whalerock Point Partners LLC Acquires 553 Shares of Amgen, Inc. (AMGN)

Whalerock Point Partners LLC increased its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 8.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,477 shares of the medical research company’s stock after purchasing an additional 553 shares during the quarter. Whalerock Point Partners LLC’s holdings in Amgen were worth $1,394,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in AMGN. Private Advisor Group LLC lifted its stake in Amgen by 6.8% in the first quarter. Private Advisor Group LLC now owns 46,776 shares of the medical research company’s stock valued at $7,589,000 after acquiring an additional 2,980 shares during the last quarter. Congress Asset Management Co. MA lifted its stake in Amgen by 1.8% in the first quarter. Congress Asset Management Co. MA now owns 35,902 shares of the medical research company’s stock valued at $5,890,000 after acquiring an additional 634 shares during the last quarter. Aberdeen Asset Management PLC UK lifted its stake in Amgen by 2.6% in the first quarter. Aberdeen Asset Management PLC UK now owns 555,638 shares of the medical research company’s stock valued at $91,164,000 after acquiring an additional 14,034 shares during the last quarter. Chatham Capital Group Inc. lifted its stake in Amgen by 1.8% in the first quarter. Chatham Capital Group Inc. now owns 2,330 shares of the medical research company’s stock valued at $382,000 after acquiring an additional 41 shares during the last quarter. Finally, GWM Advisors LLC lifted its stake in Amgen by 259.7% in the first quarter. GWM Advisors LLC now owns 9,830 shares of the medical research company’s stock valued at $1,592,000 after acquiring an additional 7,097 shares during the last quarter. Institutional investors and hedge funds own 78.46% of the company’s stock.

In related news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $176.83, for a total transaction of $269,665.75. Following the transaction, the executive vice president now directly owns 56,106 shares of the company’s stock, valued at $9,921,223.98. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Carbonnel Francois De sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total transaction of $694,440.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 8,575 shares of company stock worth $1,509,339. 0.19% of the stock is owned by insiders.

A number of brokerages have commented on AMGN. Royal Bank of Canada began coverage on shares of Amgen in a research note on Thursday, September 14th. They issued a “sector perform” rating and a $192.00 price target for the company. Bank of America increased their price target on shares of Amgen to $210.00 and gave the company a “buy” rating in a research note on Thursday, October 5th. Oppenheimer reiterated a “buy” rating and issued a $203.00 price target on shares of Amgen in a research note on Friday, October 6th. Mizuho reissued a “buy” rating and issued a $198.00 price objective on shares of Amgen in a research report on Friday, October 6th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $196.00 price objective (up from $189.00) on shares of Amgen in a research report on Friday, October 6th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and ten have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $190.15.

Amgen, Inc. (AMGN) opened at $180.34 on Thursday. Amgen, Inc. has a 1 year low of $147.12 and a 1 year high of $191.10. The company has a market cap of $130,910.00, a PE ratio of 16.29, a P/E/G ratio of 2.55 and a beta of 1.36. The company has a debt-to-equity ratio of 1.05, a quick ratio of 5.72 and a current ratio of 6.07.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The business had revenue of $5.77 billion for the quarter, compared to analyst estimates of $5.75 billion. During the same period last year, the firm earned $3.02 earnings per share. Amgen’s revenue for the quarter was down .7% compared to the same quarter last year. analysts anticipate that Amgen, Inc. will post 12.71 EPS for the current year.

Amgen declared that its board has approved a share repurchase program on Wednesday, October 25th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical research company to repurchase shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company’s board believes its shares are undervalued.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 8th. Investors of record on Thursday, February 15th will be given a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a yield of 2.93%. This is a positive change from Amgen’s previous quarterly dividend of $1.15. The ex-dividend date is Wednesday, February 14th. Amgen’s dividend payout ratio (DPR) is currently 41.55%.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.com-unik.info/2018/01/04/whalerock-point-partners-llc-acquires-553-shares-of-amgen-inc-amgn.html.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit